Trial Profile
A multicenter, randomized, blinded, double-dummy, placebo controlled, 3-period cross-over study to evaluate the effect of QVA149 on patient reported dyspnea in moderate to severe chronic obstructive pulmonary disease (COPD), using tiotropium as an active control.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Feb 2015
Price :
$35
*
At a glance
- Drugs Glycopyrrolate/indacaterol (Primary) ; Tiotropium bromide
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Acronyms BLAZE
- Sponsors Novartis
- 23 Sep 2013 Results from this trial contributed to the approval of glycopyrrolate/indacaterol, delivered via the Ultibro Breezhaler, by the European Commission according to a Vectura Group media release.
- 11 Sep 2013 Results presented at the 23rd Annual Congress of the European Respiratory Society.
- 11 Sep 2013 Results presented at the 23rd Annual Congress of the European Respiratory Society.